A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

NCT01332552 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

27

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to unfavorable human pharmacokinetic properties

Conditions

Hepatitis C

Interventions

DRUG: GSK2485852 70 mg
DRUG: GSK2485852 420 mg
DRUG: placebo
DRUG: placebo
DRUG: GSK2485852 420 mg
DRUG: GSK2485852 420 mg
DRUG: GSK2485852 630 mg
DRUG: GSK2485852 70 mg + Ritonavir 100mg
DRUG: GSK2485852 210 mg + Ritonavir 100mg
DRUG: GSK2485852 210 mg +Ritonavir 100mg

Sponsor

GlaxoSmithKline